You are here

AstraZeneca

AstraZeneca's Calquence steps up to challenge Imbruvica with big CLL green light

Fierce Pharma

Thu, 11/21/19 - 06:26 pm

AZ, Merck and Novartis top Big Pharma's Q3 growth charts. Teva and Pfizer? Not so much

Fierce Pharma

Tue, 11/19/19 - 11:38 pm

AHA: AstraZeneca's Brilinta linked to less bleeding solo than as an aspirin add-on

Fierce Pharma

Sun, 11/17/19 - 08:35 pm

AHA: AstraZeneca's Farxiga outcomes data looks even better in patients without diabetes

Fierce Pharma

Sat, 11/16/19 - 10:42 pm

AstraZeneca, Merck win red carpet treatment at the FDA as a 3-time loser seeks speedy OK for rare tumors

Endpoints

Thu, 11/14/19 - 10:21 am

AstraZeneca plans 2020 filing for anifrolumab in lupus

Fierce Biotech

Tue, 11/12/19 - 10:25 am

Data From 3 Roxadustat Trials Lead Off Kidney Week Sessions Ahead of Efficacy, Safety News

Managed Markets Network

Sat, 11/9/19 - 12:12 pm

Top execs from AstraZeneca, Roche, Sanofi and GSK tout China investments at import expo

Fierce Pharma

Thu, 11/7/19 - 10:21 am

AstraZeneca creates $1B Chinese fund, vows to double R&D team

Fierce Biotech

Wed, 11/6/19 - 10:38 am

Daiichi Sankyo takes Seattle Genetics to court as battle over breast cancer drug escalates

Pharmaforum

Wed, 11/6/19 - 10:18 am

Seattle Genetics

trastuzumab deruxtecan

Daiichi sues Seattle Genetics over tech used in high-profile ADC

Fierce Biotech

Tue, 11/5/19 - 10:34 am

Seattle Genetics

antibody-drug conjugate

AstraZeneca tops first Pharmaceutical Invention Index

Pharma Letter

Mon, 11/4/19 - 10:04 am

Is AbbVie's Imbruvica concerned about AZ's rising Calquence? We've got this covered, execs say

Fierce Pharma

Fri, 11/1/19 - 06:55 pm

AstraZeneca to sell anti-psychotic medicine rights in Europe and Russia for $239m

Pharmaceutical Business Review

Thu, 10/31/19 - 10:14 am

AstraZeneca, on BMS' heels, scores lung cancer win with Imfinzi combos

Fierce Pharma

Tue, 10/29/19 - 10:25 am

non-small cell lung cancer

AstraZeneca Beats Expectations, China Momentum Continues — Earnings Review

Morningstar

Thu, 10/24/19 - 10:41 am

AstraZeneca dumps phase 3 renal cell carcinoma program

Fierce Biotech

Thu, 10/24/19 - 10:23 am

renal cell carcinoma

What's in the Cards for AstraZeneca (AZN) in Q3 Earnings?

Yahoo/Zacks.com

Tue, 10/22/19 - 10:36 am

AstraZeneca's Farxiga scores FDA nod to cut risk of hospitalization for heart failure in diabetics

Endpoints

Mon, 10/21/19 - 10:08 am

type 1 diabetes

A change of the guard for the world’s biggest cancer companies

EP Vantage

Fri, 10/18/19 - 10:16 am

Bristol-Myers Squibb

Pages